Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MHRA advice on rosiglitazone

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a statement following the publication of a meta-analysis in the New England Journal of Medicine linking rosiglitazone with cardiovascular events.

The publication of the original paper has already been covered, as has the FDA response to the study.

The MHRA have highlighted that the product information for rosiglitazone has carried warnings about heart failure since 2000 and myocardial infarction since 2006.

The MHRA advice is that "patients should not stop treatment with rosiglitazone but should discuss their medication with their doctor at their next routine appointment".

Action: Clinicians should be aware of the MHRA advice and discuss alternative treatment options with patients currently taking rosiglitazone at their next routine appointment.

Share 'MHRA advice on rosiglitazone' on Email Share 'MHRA advice on rosiglitazone' on Delicious Share 'MHRA advice on rosiglitazone' on Digg Share 'MHRA advice on rosiglitazone' on Facebook Share 'MHRA advice on rosiglitazone' on Google+ Share 'MHRA advice on rosiglitazone' on reddit Share 'MHRA advice on rosiglitazone' on StumbleUpon Share 'MHRA advice on rosiglitazone' on Twitter

atomic-wealth

One Comments to “MHRA advice on rosiglitazone”

  1. […] fails to provide any reassurance with respect to the cardiovascular safety of rosiglitazone. MHRA advice recommends that patients currently taking rosiglitazone discuss the risks and benefits of continued […]

    Pingback by Rosiglitazone defence unconvincing | Prescribing Advice for GPs — June 6, 2007 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,217 spam comments.

atomic-wealth
fond-illness
summer